Benefits of statins in cerebrovascular disease

Current Opinion in Investigational Drugs

Volumn 5, Issue 3, 2004, Pages 295-305

  Di Napoli, Mario ^a  

^a SMDN Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention   (Italy)

Author keywords

Cerebrovascular disease; Ischemia; Low density lipoprotein cholesterol; Nitric oxide; Statins; Stroke

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CEREBROVASCULAR ACCIDENT; CHEMISTRY; CLINICAL TRIAL; HUMAN; REVIEW; RISK FACTOR;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 3042573213     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Sans S, Kesteloot H, Kromhout D: The burden of cardiovascular disease mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J (1997) 18(8):1231-1248.
2. Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J: International trends in mortality from stroke, 1968 to 1994. Stroke (2000) 31(7):1588-1601.
3. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet (2002) 360(9326):7-22.
4. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Am Med Assoc (2002) 288(23):2998-3007.
5. Pasternak RC: The ALLHAT lipid lowering trial - less is less. J Am Med Assoc (2002) 288(23):3042-3044.
6. Prospective Studies Collaboration: Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet (1995) 346(8991-8992):1647-1653.
7. Horenstein RB, Smith DE, Mosca L: Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke (2002) 33(7):1863-1868.
8. Benfante R, Yano K, Hwang LJ, Curb JD, Kagan A, Ross W: Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke (1994) 25(4):814-820.
9. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med (1989) 320(14):904-910.
10. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR: Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study. Stroke (2003) 34(3):623-631.
11. Engström G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F: Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation (2002) 105(22):2632-2637.
12. Yano K, Reed DM, MacLean CJ: Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke (1989) 20(11):1460-1465.
13. Dyker AG, Weir CJ, Lees KR: Influence of cholesterol on survival after stroke: Retrospective study. Br Med J (1997) 314(7094):1584- 1588.
14. Vauthey C, de Freitas GR, van Melle G, Devuyst G, Bogousslavsky J: Better outcome after stroke with higher serum cholesterol levels. Neurology (2000) 54(10):1944-1949.
15. Di Mascio R, Marchioli R, Tognoni G: Cholesterol reduction and stroke occurrence: An overview of randomized clinical trials. Cerebrovasc Dis (2000) 10(2):85-92.
16. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P: Differential effects of lipid-lowering therapies on stroke prevention: A meta-analysis of randomized trials. Arch Intern Med (2003) 163(6):669-676.
17. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344(8934):1383-1389.
18. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 333(20):1301-1307.
19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med (1996) 335(14):1001-1009.
20. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc (1998) 279(20):1615-1622.
21. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med (1998) 339(19):1349-1357.
22. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet (2003) 361(9364):1149-1158.
23. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J (1998) 19(10):1434-1503.
24. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol (2003) 92(2):152-160.
25. Jones P, Kafonek S, Laurora I, Hunninghake D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol (1998) 81(5):582-587.
26. Olsson AG, Pauciullo P, Soska V, Luley C, Pieters RE, Broda G, Palacios B: Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: A randomized trial. Clin Ther (2001) 23(1):45-61.
27. Saito Y, Yamada N, Teramoto T, Itakura H, Hata Y, Nakaya N, Mabuchi H, Tushima M, Sasaki J, Ogawa N, Gotto Y: A randomized, doubleblind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis (2002) 162(2):373-379.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc (2001) 285(19):2486-2497.
29. Lablanche J-M: Achieving LDL-C target levels: The role of statins. Curr Med Res Opin (2001) 16(4):285-295.
30. White HD, Simes J, Anderson NE, Hankey GJ, Watson JDG, Hunt D, Colquhoun DM, Glasziou P, MacMahon S, Kirby AC, West MJ et al: Pravastatin therapy and the risk of stroke. N Engl J Med (2000) 343(5):317-326.
31. Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA, Tobert JA, Haghfelt T: Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol (1998) 81(3):333-335.
32. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pffefer MA, Bernstein V, Cuddy TE, Moye LA, Piller LB, Rutherford J, Simpson LM et al: Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 99(2):216-223.
33. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J: Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation (2001) 103(3):387-392.
34. Warshafsky S, Packard D, Marks SJ, Sachdeva N, Terashita DM, Kaufman G, Sang K, Deluca AJ, Peterson SJ, Frishman WH: Efficacy of 3-hydroxy- methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. J Gen Intern Med (1999) 14(12):763-774.
35. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ: Stroke, statins, and cholesterol. A meta-analysis of randomized, placebocontrolled, double-blind trials with HMG-CoA reductase inhibitors. Stroke (1997) 28(5):946-950.
36. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T: Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation (2002) 106(13):1690-1695.
37. Aronow WS, Ahn C, Gutstein H: Incidence of new atherothrombotic brain infarction in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥ 125 mg/dl treated with statins versus no lipid-lowering drug. J Gerontol A Biol Sci Med Sci (2002) 57(5):M333-M335.
38. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM et al: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet (2002) 360(9346):1623-1630.
39. Alberts MJ: Suppression of recurrent transient ischemic attacks by a statin agent. Neurology (2001) 56(4):531-532.
40. Callahan A: Cerebrovascular disease and statins: A potential addition to the therapeutic armamentarium for stroke prevention. Am J Cardiol (2001) 88(7B):33J-37J.
41. Kaste M: Statins in threatened stroke. Stroke (2003) 34(2):351-353.
42. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ: Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation (2001) 103(23):2828-2833.
43. Crouse JR 3rd, Byington RP, Bond MG, Espeland MG, Craven TE, Sprinkle JW, McGovern ME, Furberg CD: Pravastatin, Lipids, and Atherosclerosis in the Carotid arteries (PLAC-II). Am J Cardiol (1995) 75(7):455-459.
44. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation (1994) 90(4):1679-1687.
45. Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, Chauvel C, Touboul PJ, Bousser MG: Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med (1994) 331(22):1474- 1479.
46. Alfon J, Pueyo Palazon C, Royo T, Badimon L: Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost (1999) 81(5):822-827.
47. Grobbee DE, Bots ML: Statin treatment and progression of atherosclerotic plaque burden. Drugs (2003) 63(9):893-911.
48. Libby P, Aikawa M: Mechanisms of plaque stabilization with statins. Am J Cardiol (2003) 91(4A):4B-8B.
49. Kurata T, Kurata M, Okada T: Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia. J Int Med Res (2001) 29(4):329-334.
50. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol (1998) 18(11):1671-1678.
51. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P: An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation (2001) 103(2):276-283.
52. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M, Aikawa M: Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation (2001) 103(7):993-999.
53. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation (2001) 103(7):926-933.
54. Bernini F, Didoni G, Bonfadini G, Bellosta S, Fumagalli R: Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis (1993) 104(1-2):19-26.
55. Bernini F, Scurati N, Bonfadini G, Fumagalli R: HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol (1995) 15(9):1352-1358.
56. Laufs U, Liao JK: Targeting Rho in cardiovascular disease. Circ Res (2000) 87(7):526-528.
57. Laufs U, Liao JK: Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med (2000) 10(4):143-148.
58. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, Corsini A: Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis (1998) 137(Suppl):S101- S109.
59. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature (1990) 343(6257):425-430.
60. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclindependent kinases controls DNA replication by interaction with PCNA. Nature (1994) 369(6481):574-578.
61. Müller C, Kiehl MG, van de Loo J, Koch OM: Lovastatin induces p21WAF1/Cip1 in human vascular smooth muscle cells: Influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition. Int J Mol Med (1999) 3(1):63-68.
62. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation (2002) 105(9):1135-1143.
63. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 347(20):1557-1565.
64. Weitz-Schmidt G: Statins as anti-inflammatory agents. Trends Pharmacol Sci (2002) 23(10):482-486.
65. Inzitari D, Eliasziw M, Gates P, Sharpe BL, Chan RKT, Meldrum HE, Barnett HJM: The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med (2000) 342(23):1693-1700.
66. Martin R, Bogousslavsky J: Mechanism of late stroke after myocardial infarct: The Lausanne Stroke Registry. J Neurol Neurosurg Psychiatry (1993) 56(7):760-764.
67. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G: Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation (2001) 104(9):982-985.
68. Nahrendorf M, Hu K, Hiller KH, Galuppo F, Fraccarollo D, Schweizer G, Hasse A, Ertl G, Bauer WR, Bauersachs J: Impact of hydroxymethylglutaryl coenzyme A reductase inhibition on left ventricular remodeling after myocardial infarction: An experimental serial cardiac magnetic resonance imaging study. J Am Coll Cardiol (2002) 40(9):1695-1700.
69. Rosenson RS: Biological basis for statin therapy in stroke prevention. Curr Opin Neurol (2000) 13(1):57-62.
70. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyörälä K: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Cardiac Failure (1997) 3(4):249-254.
71. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. J Am Med Assoc (1998) 279(20):1643-1650.
72. Chen LY, Mehta P, Mehta LJ: Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: Relevance of the effect of oxidized LDL on platelet function. Circulation (1996) 93(9):1740-1746.
73. Hassall DG, Owen JS, Bruckdorfer KR: The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin. Biochem J (1983) 216(1):43-49.
74. Broze GJ Jr: The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol (1992) 29(3):159-169.
75. 2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin. Arterioscler Thromb Vasc Biol (1995) 15(6):759-764.
76. Carvalho AC, Colman RW, Lees RS: Platelet function in hyperlipoproteinemia. N Engl J Med (1974) 290(8):434-438.
77. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF: Statin prevents tissue factor expression in human endothelial cells: Role of Rho/Rho-kinase and Akt pathways. Circulation (2002) 105(15):1756-1759.
78. Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H, Miyamori I: Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol (2003) 23(3):512-517.
79. Baetta R, Camera M, Comparato C, Altana C, Ezekowitz MD, Tremoli E: Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thomb Vasc Biol (2002) 22(4):692-698.
80. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M: Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke (2000) 31(10):2442-2449.
81. Mayer J, Eller T, Brauer P, Solleder EM, Schafer RM, Keller F, Kochsiek K: Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol (1992) 64(4):196-201.
82. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D: Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation (1995) 92(11):3172-3177.
83. Dangas G, Smith DA, Unger AH, Shao JH, Meraj P, Fier C, Cohen AM, Fallon JT, Badimon JJ, Ambrose JA: Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost (2000) 83(5):688-692.
84. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A: Simvastatin depresses blood clotting by inhibiting activation of prothrombin, Factor V, and Factor XIII and by enhancing Factor Va inactivation. Circulation (2001) 103(18):2248-2253.
85. Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Angori P, Auteri A, Bruni F: Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest (2002) 32(12):901-908.
86. Ma LP, Nie DN, Hsu SX, Yin SM, Xu LZ, Nunes JV: Inhibition of platelet aggregation and expression of α granule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia. J Assoc Acad Minor Phys (2002) 13(1):23-26.
87. Di Napoli M: HMG-CoA reductase inhibitors (statins): A promising approach to stroke prevention. Neurology (2000) 55(7):1066- 1067.
88. Jonsson N, Asplund K: Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke (2001) 32(5):1112-1115.
89. Di Napoli M, Papa F: Inflammation, statins, and outcome after ischemic stroke. Stroke (2001) 32(10):2446-2447.
90. Dalkara T, Yoshida T, Irikura K, Moskowitz MA: Dual role of nitric oxide in focal cerebral ischemia. Neuropharmacology (1994) 33(11):1447-1452.
91. Vaughan CJ, Delanty N: Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke (1999) 30(9):1969-1973.
92. Liao JK: Statins and ischemic stroke. Atherosclerosis Suppl (2002) 3(1):21-25.
93. Laufs U: Beyond lipid-lowering: Effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol (2003) 58(11):719-731.
94. Laufs U, Liao JK: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem (1998) 273(37):24266-24271.
95. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M: Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res (2002) 942(1-2):23-30.
96. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA (1998) 95(15):8880-8885.
97. Gertz K, Laufs U, Lindauer U, Nickenig G, Bohm M, Dirnagl U, Endres M: Withdrawal of statin treatment abrogates stroke protection in mice. Stroke (2003) 34(2):551-557.
98. Kim JS: Cytokines and adhesion molecules in stroke and related diseases. J Neurol Sci (1996) 137(2):69-78.
99. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci (1999) 22(9):391-397.
100. Becker KJ: Targeting the central nervous system inflammatory response in ischemic stroke. Curr Opin Neurol (2001) 14(3):349-353.
101. Di Napoli M, Papa F, Bocola V: C-reactive protein in ischemic stroke: An independent prognostic factor. Stroke (2001) 32(4):917-924.
102. Di Napoli M, Papa F: Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke (2002) 33(7):1763-1771.
103. Liu T, McDonnell PC, Young PR, White RF, Siren AL, Hallenbeck JM, Barone FC, Feurestein GZ: Interleukin-1p mRNA expression in ischemic rat cortex. Stroke (1993) 24(11):1746-1750.
104. Ambrosio G, Tritto I: Reperfusion injury: Experimental evidence and clinical implications. Am Heart J (1999) 138(2 Pt 2):S69-S75.
105. Frijns CJ, Kappelle LJ: Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke (2002) 33(8):2115- 2122.
106. Tak PP, Firestein GS: NF-κB: A key role in inflammatory diseases. J Clin Invest (2001) 107(1):7-11.
107. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M: NF-κB is activated and promotes cell death in focal cerebral ischemia. Nat Med (1999) 5(5):554-559.
108. Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, Davalos A: Inflammation-mediated damage in progressing lacunar infarctions: A potential therapeutic target. Stroke (2002) 33(4):982-987.
109. Love S, Barber R: Expression of P-selectin and intercellular adhesion molecule-1 in human brain after focal infarction or cardiac arrest. Neuropathol Appl Neurobiol (2001) 27(6):465-473.
110. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MPS, Nilsson J, Pachinger O, Weidinger F: HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2003) 23(1):58-63.
111. Pahan K, Sheikh FG, Namboodiri AM, Singh I: Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest (1997) 100(11):2671-2679.
112. Romano M, Mezzetti A, Marulli C, Ciabattoni G, Febo F, Di Ienno S, Roccaforte S, Vigneri S, Nubile G, Milani M, Davì G: Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: Role of nitric oxide. J Invest Med (2000) 48(3):183-189.
113. Seljeflot I, Tonstad S, Hjermann I, Arnsen H: Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis (2002) 162(1):179-185.
114. Pruefer D, Scalia R, Lefer AM: Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol (1999) 19(12):2894-2900.
115. Stalker TJ, Lefer AM, Scalia R: A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects in the microvascular endothelium: The role of mevalonic acid. Br J Pharmacol (2001) 133(3):406-412.
116. Kawashima S, Yamashita T, Miwa Y, Ozaki M, Namiki M, Hirase T, Inoue N, Hirata K, Yokoyama M: HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke (2003) 34(1):157-163.
117. Kanno T, Abe K, Yabuki M, Akiyama J, Yasuda T, Horton AA: Selective inhibition of formyl-methionyl-leucyl-phenylalanine (fMLF)-dependent superoxide generation in neutrophils by pravastatin, an inhibitor of 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase. Biochem Pharmacol (1999) 58(12):1975-1980.
118. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 100(3):230-235.
119. Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. J Am Med Assoc (2001) 286(1):64-70.
120. Ikeda U, Ito T, Shimada K: Statins and C-reactive protein. Lancet (1999) 353(9160):1274-1275.
121. Ridker PM: High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation (2001) 103(13):1813-1818.
122. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, Zhang C, Lu M, Katakowski M, Feldkamp CS, Chopp M: Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol (2003) 53(6):743-751.
123. Zhang ZG, Zhang L, Tsang W, Soltanian-Zadeh H, Morris D, Zhang R, Goussev A, Powers C, Yeich T, Chopp M: Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab (2002) 22(4):379-392.
124. Ford I, Blauw G, Murphy MB, Shepherd J, Cobbe SM, Bollen EL, Buckley BM, Jukema JW, Hyland M, Gaw A, Lagaay AM et al: A Prospective Study of Pravastatin in the Eldery at Risk (PROSPER): Screening experience and baseline characteristics. Curr Control Trials Cardiovasc Med (2002) 3(1):8.
125. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. J Am Med Assoc (2001) 285(13):1711-1718.
126. Di Napoli M: Does treatment with statins improve stroke prognosis. Cardiovasc Rev Rep (2002) 23:572-580.